Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback